TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Telik

Status and phase: Completed; Phase 2; Phase 1

Conditions: Non-small Cell Lung Cancer

Treatments: Drug: TLK286, cisplatin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00077883

TLK286.2021

Details and patient eligibility

About

The purpose of this trial is to study the efficacy and safety of the combination of TLK286 with cisplatin as first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer.

Enrollment: 50 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 years of age or older
• Histologically confirmed non-small cell lung cancer
• Stage IV or IIIB
• Measurable disease by RECIST
• ECOG performance status of 0-1
• Adequate liver and renal function
• Adequate bone marrow reserve

Exclusion criteria

• History of bone marrow transplantation or stem cell support
• Pregnant or lactating women

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)